Skip to content
PubMed This is a summary of 48 peer-reviewed journal articles Updated
Neurology · Parkinson disease 25, autosomal recessive, with impaired intellectual development

PARK25 (PTPA-Related Parkinsonism): A Patient Guide

At a Glance

PARK25 is an ultra-rare inherited condition caused by harmful changes in the PPP2R4 gene. It combines parkinsonism—stiffness, slowed movement, and tremor that often begin in adolescence—with intellectual disability; some people respond to carefully monitored levodopa.

PARK25, also known as PTPA-related parkinsonism, is an ultra-rare genetic condition that, in the reported individuals, typically begins to show its physical signs during the teenage years. For many families, receiving this diagnosis is the end of a long “diagnostic odyssey,” providing a name for a complex set of symptoms that include both movement challenges and intellectual disability. While the condition is lifelong, understanding its genetic cause—pathogenic variants in the PPP2R4 gene (formerly known as PTPA)—allows for a more targeted approach to care and helps distinguish it from other conditions that may look similar but require different treatments [1][2].

What is Known and What is Still Uncertain

Because PARK25 has been reported in only a few families worldwide as of recently, its natural history remains uncertain. Care must be highly individualized, and the observations below are based on limited case reports, not broad population studies.

The condition involves motor and neurodevelopmental features. The movement symptoms, known as parkinsonism, often involve muscle stiffness, slowness of movement, and tremors that emerge in adolescence. At the same time, individuals with PARK25 live with a foundational intellectual disability that is usually present from early childhood. Unlike some other neurodegenerative diseases, the cognitive challenges in reported individuals tend to remain relatively stable over time, rather than following a path of rapid decline [1].

One of the most encouraging aspects of PARK25 is that the motor symptoms in some reported individuals have shown a “marked and sustained” response to a carefully monitored trial of levodopa, a standard medication used to manage Parkinson’s symptoms. This means that while the underlying genetic mutation cannot yet be fixed, some of the physical challenges may be managed medically. However, benefit and adverse effects vary, and response should not be used alone for prognosis. Because the condition is so rare, a specialized, multidisciplinary care team is essential to balance medication and supportive therapies [1][2].

Whether you are the diagnosed person or a caregiver, your observations are a vital part of the medical record. Because PARK25 affects each person differently, your partnership with specialists in movement disorders and genetics is the key to navigating the road ahead. While a diagnosis of an ultra-rare condition is significant, it also provides a roadmap for support, connecting you to a growing global understanding of this specific genetic pathway and the treatments that help manage it [1].

Common questions in this guide

What is PARK25, and what causes it?
PARK25 is an ultra-rare inherited condition that combines parkinsonism with intellectual disability. It is linked to harmful changes in the PPP2R4 gene, which was formerly called PTPA.
What symptoms usually appear with PARK25?
Intellectual disability is usually present from early childhood. In reported individuals, movement symptoms often become noticeable during the teenage years and may include muscle stiffness, slowed movement, and tremor.
Can levodopa help with PARK25 movement symptoms?
Some reported individuals have had a marked and sustained improvement in movement with a carefully monitored levodopa trial. The benefit and side effects vary, and a response to levodopa should not be used by itself to predict the long-term outlook.
Does intellectual disability change how PARK25 is treated?
Care should be tailored to the person’s communication, daily functioning, and movement needs. A multidisciplinary team can combine medication with supportive therapies and consider the person’s baseline abilities and quality-of-life goals.
Which specialists should be involved in PARK25 care?
Care commonly involves specialists in movement disorders and medical genetics, with other professionals added according to the person’s needs. Genetic counseling can help families understand the diagnosis and discuss whether other relatives should seek evaluation.
How certain is what doctors know about PARK25’s long-term course?
Only a few families with PARK25 have been reported, so its long-term course is not fully known. In the reported individuals, intellectual disability has tended to remain relatively stable, but movement symptoms, treatment response, and support needs can differ.
How might a PPP2R4 diagnosis change treatment compared with a general Parkinson’s diagnosis?
Identifying PPP2R4-related PARK25 can help clinicians distinguish it from other conditions and set more individualized goals. Because the condition is extremely rare, there is no single treatment plan; specialists consider movement symptoms, intellectual disability, side effects, and quality-of-life goals.

Get notified when new evidence is published on Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (2)
  1. 1

    PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability.

    Fevga C, Tesson C, Carreras Mascaro A, et al.

    Brain : a journal of neurology 2023; (146(4)):1496-1510 doi:10.1093/brain/awac326.

    PMID: 36073231
  2. 2

    Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.

    Li C, Lin J, Jiang Q, et al.

    Movement disorders : official journal of the Movement Disorder Society 2023; (38(6)):1099-1104 doi:10.1002/mds.29411.

    PMID: 37046398

This page is for informational purposes only and does not constitute medical advice about PARK25. A movement-disorders specialist and genetics team can interpret the diagnosis and tailor treatment for the individual.